UC loses patent battle over prostate cancer drug in SA

Original Article by Kabelo Khumalo | Business Day | 4 March 2025

The University of California's (UC) patent for Xtandi, a prostate cancer drug, was revoked in South Africa, allowing generic alternatives to enter the market.

The University of California’s (UC) patent for Xtandi, a prostate cancer drug, was revoked in South Africa, allowing generic alternatives to enter the market.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here